Notice: Educational content. Affiliate links may be present - we may earn commission at no extra cost to you. Not medical advice. Consult your physician.
Status update — September 20, 2026
Retatrutide remains investigational and NOT FDA-approved; in Lilly’s words it “cannot be legally sold or marketed for human use” (press release, July 23, 2026). Lilly has announced topline Phase 3 results by press release — TRIUMPH-4 (Dec 11, 2025; 28.7% mean weight loss at 12 mg vs 2.1% placebo, 68 weeks), TRIUMPH-1 (May 21, 2026; 28.3% vs 2.2%, 80 weeks), TRIUMPH-2 and TRIUMPH-3 (Jul 23, 2026; 20.8% and 22.6%) — which are company-reported and not yet peer-reviewed. The only peer-reviewed Phase 3 publication is TRANSCEND-T2D-1 in type-2 diabetes (The Lancet, June 2026, PMID 42250575). Lilly says it plans to submit a Biologics License Application (BLA) in Q1 2027 — a company projection, not an FDA decision or date. TRIUMPH-2 is scheduled for presentation at EASD 2026 (Milan, Sep 28–Oct 2), a future presentation as of this update.
Separately, two oral GLP-1 medicines are now FDA-approved for weight management: Wegovy tablets 25 mg (Dec 22, 2025) and Foundayo (orforglipron, Apr 1, 2026; maximum 17.2 mg once daily). Earlier estimates on this page that predate these announcements are kept for context. Sources: investor.lilly.com; ClinicalTrials.gov NCT05929066, NCT05929079, NCT05882045, NCT05931367 (completed; results not yet posted).
Every regulatory milestone toward FDA approval - tracked live. Estimates based on Eli Lilly public statements and historical FDA review patterns.
Estimated time to FDA approval
Target: PDUFA decision Q4 2027 (estimated). Not a guarantee.
From clinical trials to your pharmacy. Where retatrutide is right now.
Safety & Pharmacokinetics
Dose-Range Efficacy (24.2% weight loss)
TRIUMPH Program (7 trials)
TRIUMPH-4 done (28.7% weight loss). TRIUMPH-1, 2, 3, 5, MASH expected 2026. CVOT ongoing.
FDA New Drug Application
PDUFA Decision
Every disclosed clinical and regulatory event, in order.
| Milestone | Date | Status | Source |
|---|---|---|---|
| Phase 1 first-in-human dosing | 2018 | Done | Eli Lilly pipeline disclosure |
| TRIUMPH Phase 2 results published (24.2% weight loss) | August 2023 | Done | Jastreboff NEJM 2023, PMID 37364103 |
| Phase 3 TRIUMPH program initiated | 2024 | Done | ClinicalTrials.gov registry |
| TRIUMPH-4 enrollment closed | 2024 | Done | ClinicalTrials.gov NCT05929066 |
| TRIUMPH-4 topline results (28.7% weight loss) | December 2025 | Done | Eli Lilly press release Dec 2025 |
| TRIUMPH-1 (obesity primary efficacy) topline | Q2-Q3 2026 | Estimated | Eli Lilly Q1 2026 earnings call |
| TRIUMPH-2 (longer-term safety) topline | Q3 2026 | Estimated | Eli Lilly disclosed schedule |
| TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (obesity + CVD) topline — announced by Lilly Jul 23, 2026 | Announced Jul 23, 2026 | Estimated | Eli Lilly disclosed schedule |
| TRIUMPH-5 (sleep apnea) + TRIUMPH-MASH topline | Throughout 2026 | Estimated | Eli Lilly disclosed schedule |
| BLA submission to FDA | Q1 2027 (Lilly plan, Jul 23, 2026) | Estimated | Lilly investor calls + FDA pathway |
| FDA filing acceptance (60-day review) | ~60 days post-NDA | Estimated | FDA CDER PDUFA guidelines |
| FDA Priority Review designation request | 2027 (with NDA) | Estimated | FDA Priority Review pathway criteria |
| PDUFA decision (FDA approval/rejection) | Late 2027 (estimated) | Estimated | FDA PDUFA standard 10-month clock |
| Manufacturing scale-up + commercial launch | Q1-Q2 2028 | Estimated | Tirzepatide post-approval pattern |
Free dedicated alerts list. Within 24 hours of any TRIUMPH readout, NDA filing, FDA decision, or commercial launch.
Free. No spam. Unsubscribe anytime.
Historical Phase 3 to FDA approval, used to project retatrutide.
Semaglutide
~4 years
Phase 3 STEP started 2018 - FDA Wegovy approval June 2021
Tirzepatide
~3 years
Phase 3 SURPASS started 2018 - FDA Mounjaro approval May 2022
Retatrutide (projected)
~3 years
Phase 3 TRIUMPH started 2024 - FDA approval estimated late 2027
Why retatrutide may match tirzepatide's timeline: Eli Lilly is the same sponsor for both compounds. The regulatory experience, FDA relationship, and parallel Phase 3 trial design suggest similar review efficiency. The 28.7% TRIUMPH-4 result strengthens the case for Priority Review (6 months instead of 10), which could move approval to mid-2027.
Based on Eli Lilly's TRIUMPH Phase 3 schedule, Lilly has stated (July 23, 2026) that it plans to submit a BLA in Q1 2027 — a company projection, not an FDA date. With a standard 10-month FDA review, PDUFA decision is projected for late 2027. Priority Review (6 months) could move approval to mid-2027. These are estimates - subject to clinical and regulatory outcomes.
No PDUFA date has been set as of September 20, 2026 because Eli Lilly has not yet submitted its application; Lilly has said it plans to submit a Biologics License Application (BLA) in Q1 2027. PDUFA dates are assigned 60 days after NDA acceptance and fall 10 months later for standard review (or 6 months for Priority Review). Estimated PDUFA window: Q3-Q4 2027.
Tirzepatide started Phase 3 SURPASS in 2018, NDA filed 2021, FDA approved as Mounjaro in May 2022 for type 2 diabetes, and as Zepbound in November 2023 for obesity. Total Phase 3 to first FDA approval: about 3 years. Retatrutide is following a similar trajectory.
Approximately 30% of NDAs receive a Complete Response Letter (CRL) on first submission, which adds 6-12 months. Other delay factors: Phase 3 safety signals, REMS requirements, manufacturing scale-up issues. Both base-case (late 2027) and delay scenarios (mid-2028) are realistic.
Yes. Use the form above to join the dedicated retatrutide alerts list. You'll receive a notification within 24 hours of any major milestone: TRIUMPH readouts, NDA filing, FDA decisions, and commercial launch. Free, no spam, unsubscribe anytime.
All dates marked "Estimated" are projections based on Eli Lilly public statements, ClinicalTrials.gov registry data, and historical FDA review patterns. They are NOT guarantees and are subject to clinical trial outcomes, FDA decisions, and regulatory contingencies. Retatrutide is investigational and is NOT FDA-approved as of September 20, 2026. Do not use products claiming to be retatrutide outside of registered TRIUMPH clinical trials. This page is educational and does not constitute medical advice. Always consult a licensed healthcare provider.
FTC affiliate disclosure - We may earn commission if you sign up to FDA-approved alternatives via our partner links. Retatrutide-specific content has no affiliate relationships.